ESH MM 2018 | Future treatment combinations for myeloma
Multiple myeloma (MM) therapy has evolved rapidly in recent years, and is showing no sign of slowing. Here, Kenneth Anderson, MD, from Harvard Medical School, Boston, MA, discusses interesting future treatment combinations from the European School of Haematology (ESH) International Conference on MM 2018. Dr Anderson highlights a number of approaches and devlopments, including the upcoming MMRF MyDRUG trial that will utilize genomic profiling and combination treatments.
Get great new content delivered to your inboxSign up